Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ex-presidente da empresa farmacêutica especializada da Shire PLC ("Shire"), com mais de 30 anos de experiência em neurociência, doenças raras e produtos farmacêuticos especializados, incluindo cargos...
-
Bekas Presiden perniagaan Farmaseutikal Khusus Shire PLC (“Shire”), dengan lebih 30 tahun pengalaman merentasi bidang neurosains, penyakit jarang jumpa dan farmaseutikal khusus, termasuk memegang...
-
Shire PLC(“Shire”) 전문의약품 사업부 전 사장으로, 신경과학·희귀질환·전문의약품 분야에서 30년 이상 경력 보유, Astra-Merck 및 AstraZeneca PLC에서 고위 리더십 역할 수행중추신경계(CNS) 프로그램 전반에 걸친 후기 임상 개발, 글로벌 상업화 및 자본 조달 분야에서 입증된 리더이번 분기 HLP004의 2상 데이터 발표...
-
• נשיא לשעבר של עסקי התרופות הייעודיות של Shire PLC ("Shire"), עם יותר מ-30 שנות ניסיון בתחומי מדעי המוח, מחלות נדירות ותרופות ייעודיות, כולל תפקידי ניהול בכירים ב-Astra-Merck ו-AstraZeneca PLC •...
-
曾出任 Shire PLC（簡稱「Shire」）專科製藥業務總裁，在神經科學、罕見疾病及專科製藥範疇擁有 30 多年豐富經驗，曾於 Astra-Merck 及 AstraZeneca PLC 擔當高層領導職務在中樞神經系統（簡稱「CNS」）項目的後期臨床開發、全球商業化及資金募集方面具備有目共睹的領導才能此任命正值 Helus Pharma...
-
WASHINGTON DC, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Buying Guide -Best Lion's Mane Mushroom Supplements in 2026 lineup by Mushcanyon Mushcanyon Earns Recognition as One of the Best Lion’s Mane...
-
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior...
-
SHEFFIELD, United Kingdom, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FundingSearch.com has been invited to participate in the Financial Conduct Authority's SME Finance TechSprint this week, marking a...
-
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that it has...
-
TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced...